Skip to main content

Monopar Therapeutics (MNPR)

Sector
Healthcare
Industry
Biotechnology
Last price
$71.06
As of

Kresmion compiles this page from MNPR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Monopar Therapeutics (MNPR): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-12.

As of . Source: SEC EDGAR filings for MNPR. Method and limitations.

COMPANY DOSSIER

See the full MNPR dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for MNPR on one page. Preview it with sample data, then open it live with a free account.

Preview the MNPR dossier

Active events for MNPR

FREE, NO ACCOUNT

Every event on MNPR, as it fires

You are seeing 5 of 7 events recorded on MNPR since 2026-05-24.

The five above landed across 4 days. The other 2 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, MNPR

More data on MNPR

MNPR against its peers

MNPR's return on equity of -10.0% ranks in the 80th percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricMNPRPeer medianPercentilen
Revenue FY0.0 USD72.3M USD1117
Gross marginn/a76.2%n/a6
Operating marginn/a-59.1%n/a15
Net marginn/a-66.0%n/a15
Return on equity-10.0%-58.4%8021
1 year-13.3%-13.6%5721

Peers (22): NGNE, OVID, DMAC, STTK, GYRE, RGNX, MDXG, CADL, CBIO, RLMD, ARVN, VALN, ZVRA, MYGN, CAPR, EPRX, PHAT, CTMX, ASMB, AVTX, SANA, ENTX. Left out: SLBT (no annual filing), BLSM (no annual filing), IAM (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (MNPR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in MNPR on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MNPR in the last 180 days.

Upstream: SEC EDGAR filings for MNPR

Kresmion, "Monopar Therapeutics (MNPR) institutional holdings and SEC filings", data as of 2026-11-14, https://kresmion.com/research/MNPR. Upstream data: SEC EDGAR filings for MNPR.

Link to this data (HTML):

<a href="https://kresmion.com/research/MNPR">Monopar Therapeutics (MNPR) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow MNPR on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MNPR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the MNPR dossier
Share

The MNPR intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.